Vainshtein JM - Search Results

1

Interval to biochemical failure predicts clinical outcomes in patients with high-risk prostate cancer treated by combined-modality radiation therapy.

Shilkrut M, McLaughlin PW, Merrick GS, Vainshtein JM, Feng FY, Hamstra DA. Shilkrut M, et al. Among authors: vainshtein jm. Int J Radiat Oncol Biol Phys. 2013 Jul 15;86(4):721-8. doi: 10.1016/j.ijrobp.2013.03.028. Epub 2013 May 9. Int J Radiat Oncol Biol Phys. 2013. PMID: 23664325

2

Limitations of the Cancer of the Prostate Risk Assessment (CAPRA) Prognostic Tool for Prediction of Metastases and Prostate Cancer-specific Mortality in Patients Treated With External Beam Radiation Therapy.

Vainshtein JM, Schipper M, Vance S, Feng FY, Olson KB, Hamstra DA. Vainshtein JM, et al. Am J Clin Oncol. 2016 Apr;39(2):173-80. doi: 10.1097/COC.0000000000000037. Am J Clin Oncol. 2016. PMID: 24487421

3

Treatment Outcomes in Very High-risk Prostate Cancer Treated by Dose-escalated and Combined-Modality Radiation Therapy.

Shilkrut M, McLaughlin PW, Merrick GS, Vainshtein JM, Hamstra DA. Shilkrut M, et al. Among authors: vainshtein jm. Am J Clin Oncol. 2016 Apr;39(2):181-8. doi: 10.1097/COC.0000000000000043. Am J Clin Oncol. 2016. PMID: 24517957

4

Patient-reported voice and speech outcomes after whole-neck intensity modulated radiation therapy and chemotherapy for oropharyngeal cancer: prospective longitudinal study.

Vainshtein JM, Griffith KA, Feng FY, Vineberg KA, Chepeha DB, Eisbruch A. Vainshtein JM, et al. Int J Radiat Oncol Biol Phys. 2014 Aug 1;89(5):973-980. doi: 10.1016/j.ijrobp.2014.03.013. Epub 2014 May 3. Int J Radiat Oncol Biol Phys. 2014. PMID: 24803039 Clinical Trial.

5

Long-term quality of life after swallowing and salivary-sparing chemo-intensity modulated radiation therapy in survivors of human papillomavirus-related oropharyngeal cancer.

Vainshtein JM, Moon DH, Feng FY, Chepeha DB, Eisbruch A, Stenmark MH. Vainshtein JM, et al. Int J Radiat Oncol Biol Phys. 2015 Apr 1;91(5):925-33. doi: 10.1016/j.ijrobp.2014.12.045. Int J Radiat Oncol Biol Phys. 2015. PMID: 25832685 Free PMC article.

6

Randomized phase II trial of urethral sparing intensity modulated radiation therapy in low-risk prostate cancer: implications for focal therapy.

Vainshtein J, Abu-Isa E, Olson KB, Ray ME, Sandler HM, Normolle D, Litzenberg DW, Masi K, Pan C, Hamstra DA. Vainshtein J, et al. Radiat Oncol. 2012 Jun 9;7:82. doi: 10.1186/1748-717X-7-82. Radiat Oncol. 2012. PMID: 22681643 Free PMC article. Clinical Trial.

7

The interval to biochemical failure is prognostic for metastasis, prostate cancer-specific mortality, and overall mortality after salvage radiation therapy for prostate cancer.

Johnson S, Jackson W, Li D, Song Y, Foster C, Foster B, Zhou J, Vainshtein J, Feng F, Hamstra D. Johnson S, et al. Int J Radiat Oncol Biol Phys. 2013 Jul 1;86(3):554-61. doi: 10.1016/j.ijrobp.2013.02.016. Epub 2013 Apr 2. Int J Radiat Oncol Biol Phys. 2013. PMID: 23561650

8

Combining prostate-specific antigen nadir and time to nadir allows for early identification of patients at highest risk for development of metastasis and death following salvage radiation therapy.

Jackson WC, Johnson SB, Foster B, Foster C, Li D, Song Y, Vainshtein J, Zhou J, Hamstra DA, Feng FY. Jackson WC, et al. Pract Radiat Oncol. 2014 Mar-Apr;4(2):99-107. doi: 10.1016/j.prro.2013.05.008. Epub 2013 Jul 18. Pract Radiat Oncol. 2014. PMID: 24890350

9

Prognostic significance of carbohydrate antigen 19-9 in unresectable locally advanced pancreatic cancer treated with dose-escalated intensity modulated radiation therapy and concurrent full-dose gemcitabine: analysis of a prospective phase 1/2 dose escalation study.

Vainshtein JM, Schipper M, Zalupski MM, Lawrence TS, Abrams R, Francis IR, Khan G, Leslie W, Ben-Josef E. Vainshtein JM, et al. Int J Radiat Oncol Biol Phys. 2013 May 1;86(1):96-101. doi: 10.1016/j.ijrobp.2012.11.020. Epub 2012 Dec 19. Int J Radiat Oncol Biol Phys. 2013. PMID: 23265573 Free PMC article. Clinical Trial.

10

Definitive Chemoradiation With Full-dose Gemcitabine for Unresectable Pancreatic Cancer: Efficacy of Involved-Field Radiotherapy.

Zhou J, Fang CX, Shen J, Schipper MJ, Zalupski MM, Minter RM, Simeone DM, Hart D, Eagle T, Kimmel GW, Vainshtein J, Lawrence TS, Feng M. Zhou J, et al. Am J Clin Oncol. 2017 Oct;40(5):517-522. doi: 10.1097/COC.0000000000000200. Am J Clin Oncol. 2017. PMID: 26165418 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

29 results

Search Page

Filters